CSIMarket


Acadia Pharmaceuticals Inc   (NASDAQ: ACAD)
Other Ticker:  
 

Acadia Pharmaceuticals Inc

ACAD's Fundamental analysis








Looking into Acadia Pharmaceuticals Inc growth rates, revenue grew by 18.28 % in III. Quarter 2024 from the same quarter a year ago. Ranking at No. 488

Major Pharmaceutical Preparations industry recorded growth of revenues by 9.75 %

Acadia Pharmaceuticals Inc realized net income compared to net loss a year ago in III. Quarter 2024

More on ACAD's Growth


Acadia Pharmaceuticals Inc
current PE on trailing twelve month basis is above Major Pharmaceutical Preparations industry average.

Acadia Pharmaceuticals Inc PEG ratio is at -0.15 Company is currently trading with Price to Cash flow multiple of 51.41 in trailing twelve-month period.
Company
26.19
PE TTM   
Industry
-
PE TTM    
Company's Price to Sales ratio is at 3.32.
Major Pharmaceutical Preparations industry's Price to Sales ratio is at 5.17.


More on ACAD's Valuation
 
 Total Debt (Millions $) -
 Dividend TTM ($) 0 $
 Dividend Yield TTM (%) -
 Revenue/Employee (TTM) $ 1,553,906
 Net Income/Employee (TTM) $ 214,893
 Receivable Turnover (TTM) 9.41
 Tangible Book Value (Per Share $) 2.84

Acadia Pharmaceuticals Inc
current PE on trailing twelve month basis is above Major Pharmaceutical Preparations industry average.

Acadia Pharmaceuticals Inc PEG ratio is at -0.15 Company is currently trading with Price to Cash flow multiple of 51.41 in trailing twelve-month period.
Company
26.19
PE TTM   
Industry
-
PE TTM    
Company's Price to Sales ratio is at 3.32.
Major Pharmaceutical Preparations industry's Price to Sales ratio is at 5.17.

Acadia Pharmaceuticals Inc Price to Book Ratio is at 5.34 lower than Industry Avg. of 88.81. and higher than S&P 500 Avg. of 0.02

More on ACAD's Valuation

  Market Capitalization (Millions $) 3,083
  Shares Outstanding (Millions) 166
  Employees 598
  Revenues (TTM) (Millions $) 929
  Net Income (TTM) (Millions $) 129
  Cash Flow (TTM) (Millions $) 60
  Capital Exp. (TTM) (Millions $) 0
  Total Debt (Millions $) -
  Dividend TTM ($) 0 $
  Dividend Yield TTM (%) -
  Revenue/Employee (TTM) $ 1,553,906
  Net Income/Employee(TTM) $ 214,893
  Receivable Turnover Ratio (TTM) 9.41
  Tangible Book Value (Per Share $) 2.84

  Market Capitalization (Millions $) 3,083
  Shares Outstanding (Millions) 166
  Employees 598
  Revenues (TTM) (Millions $) 929
  Net Income (TTM) (Millions $) 129
  Cash Flow (TTM) (Millions $) 60
  Capital Exp. (TTM) (Millions $) 0


    ACAD's Profitability Comparisons
Acadia Pharmaceuticals Inc achieved increase in profitability, due to increase in demand and cost control. Operating Margin grew in III. Quarter 2024 to 12.64 % from 12.58 % in II. Quarter.

Acadia Pharmaceuticals Inc net profit margin of 13.09 % is currently ranking no. 39 in Major Pharmaceutical Preparations industry, ranking no. 91 in Healthcare sector and number 1074 in S&P 500.


Profitability by Segment
Total 13.09 %



  Ratio
   Capital Ratio (MRQ) 2.29
  Total Debt to Equity (MRQ) -
  Tangible Leverage Ratio (MRQ) 0.85
  Asset Turnover Ratio (TTM) 1.14
  Inventory Turnover Ratio (TTM) 6.29



Acadia Pharmaceuticals Inc achieved increase in profitability, due to increase in demand and cost control. Operating Margin grew in III. Quarter 2024 to 12.64 % from 12.58 % in II. Quarter.

Acadia Pharmaceuticals Inc net profit margin of 13.09 % is currently ranking no. 39 in Major Pharmaceutical Preparations industry, ranking no. 91 in Healthcare sector and number 1074 in S&P 500.

More on ACAD's Key Ratios





Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2025 CSIMarket, Inc. All rights reserved.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com